1353100-91-0

Basic information

• Product Name: 1-H-pyrazole-4-carboxylic acid,3-broMo,ethyl ester
• Synonyms: 1-H-pyrazole-4-carboxylic acid,3-broMo,ethyl ester;3-Bromo-4-(ethoxycarbonyl)-1H-pyrazole;3-broMo-1-H-pyrazole-4-carboxylic acid ethyl ester
• CAS NO: 1353100-91-0
• Molecular Formula: C₆H₇BrN₂O₂
• Molecular Weight: 219.03598
• Product Categories: 9.7g
• Mol File: 1353100-91-0.mol

Chemical Properties

• Boiling Point: 331.1±22.0 °C(Predicted)
• Appearance: /
• Density: 1.664±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 8.58±0.50(Predicted)
• CAS DataBase Reference: 1-H-pyrazole-4-carboxylic acid,3-broMo,ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1-H-pyrazole-4-carboxylic acid,3-broMo,ethyl ester(1353100-91-0)
• EPA Substance Registry System: 1-H-pyrazole-4-carboxylic acid,3-broMo,ethyl ester(1353100-91-0)

Safety Data

• Hazardous Substances Data: 1353100-91-0(Hazardous Substances Data)

Usage

Uses

Ethyl 3-Bromo-1H-pyrazole-4-carboxylate can be used as plasma kallikrein inhibitors.

Upstream product

• 6994-25-8 3-amino-4-pyrazolecarboxylic acid ethyl ester 
• 1260243-04-6 ethyl 5-amino-1H-pyrazole-4-carboxylate 

Downstream Products

• 1355249-61-4 ethyl 3-bromo-1-(4-methoxybenzyl)-1H-pyrazole-4-carboxylate 
• 105486-72-4 5-bromo-1-methyl-1H-pyrazole-4-carboxylic acid ethyl ester 
• 139308-52-4 ethyl 3-bromo-1-methyl-1H-pyrazole-4-carboxylate 
• 116344-32-2 ethyl 1-methyl-5-phenyl-1H-pyrazole-4-carboxylate 
• 116344-31-1 ethyl 1-methyl-3-phenyl-1H-pyrazole-4-carboxylate 
• 1355249-62-5 C₁₆H₁₈N₂O₃ 

Relevant articles and documents

CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF

Disclosed herein are small molecule calpain modulator compositions, pharmaceutical compositions, the use and preparation thereof.

HETEROCYCLIC DERIVATES

The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B,W, X, Y and Z are as defined herein.

N1/N2-Lactam Acetyl-CoA carboxylase inhibitors

The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof; wherein G is R1, R2 and R3 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal

NOVEL 2-AMINO-4-PYRAZOLYL-THIAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS

The present invention relates to novel compounds of Formula (1), wherein M, A and B are defined as in Formula (I); invention compounds are modulators of metabotropic glutamate receptors - subtype 4 ("mGluR4") which are useful for the treatment or prevention of central nervous system disorders as well as other disorders modulated by mGluR4 receptors. The invention is also directed to pharmaceutical compositions and the use of such compounds in the manufacture of medicaments, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR4 is involved.

TRICYCLIC COMPOUNDS AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS

The present invention describes and claims compounds of the Structural Formula I, Structural Formula II, or Structural Formula III: wherein R1, R2, R3 and R3' are -H or methyl, or R3 and R3 taken together form a double bond, or R3' is -H and R2 and R3 taken together form a spiro-cyclopropyl substituent, R4 is -H or -F, and R5 is -H, methyl, -CI or -Br, Formula II wherein R1 is -H, ethyl-, isopropyl-, cyclopropyl-, methyl- or methoxy-, R4 is -H or -F, and "Y" is: (a) -CH2-; (b) -CR6H-0-CR7R8-, wherein R6, R7, and R8 are independently - H or methyl; (c) -CR6H-N(R9)-CR7R8-, wherein R6, R7, and R8 are independently -H or methyl; (d) -CH2-C(R9)(R10)-C(R7)(R8)-, wherein R7, R8, R9 and R10 are independently - H or -methyl, or both R7 and R8 are -F, R9 and R10 are independently -H or -methyl, or both R9 and R10 are -F, or R9 and R10 taken together are (0=), which together with the carbon to which they are attached forms a carbonyl group.

Synthesis of spiropiperidine lactam acetyl-CoA carboxylase inhibitors

The synthesis of 4′,6′-dihydrospiro[piperidine-4,5′- pyrazolo[3,4-c]pyridin]-7′(2′H)-one-based acetyl-CoA carboxylase inhibitors is reported. The hitherto unknown N-2 tert-butyl pyrazolospirolactam core was synthesized from ethyl 3-amino-1H-pyrazole-4-carboxylate in a streamlined 10-step synthesis requiring only one chromatography procedure. The described synthetic strategy provides pyrazolo-fused spirolactams from halogenated benzylic arenes and cyclic carboxylates. Key steps include a regioselective pyrazole alkylation providing the N-2 tert-butyl pyrazole and a Curtius rearrangement under both conventional and flow conditions to install the hindered amine via a stable and isolable isocyanate. Finally, a Parham-type cyclization was used to furnish the desired spirolactam. An analogous route provided efficient access to the related N-1 isopropyl lactam series. Elaboration of the lactam cores via amidation enabled synthesis of novel ACC inhibitors and the identification of potent analogues.

TRICYCLIC COMPOUNDS AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS

The present invention describes and claims compounds of the Structural Formula (I), Structural Formula (II), or Structural Formula (III). In Formula (I), R1, R2, R3 and R3' are -H or methyl, or R3 and R3' taken together form a double bond, or R3' is -H and R2 and R3 taken together form a spiro-cyclopropyl substituent, R4 is -H or -F, and R5 is -H, methyl, -Cl or -Br. In Formula (II), R1 is -H, ethyl-, isopropyl-, cyclopropyl-, methyl- or methoxy-, R4 is -H or -F, and "Y" is: (a) -CH2-; (b) -CR6H-O-CR7R8-, wherein R6, R7, and R8 are independently -H or methyl; (c) -CR6H-N(R9)-CR7R8-, wherein R6, R7, and R8 are independently -H or methyl; (d) -CH2-C(R9)(R10)-C(R7)(R8)-, wherein R7, R8, R9 and R10 are independently -H or -methyl, or both R7 and R8 are -F, R9 and R10 are independently -H or -methyl, or both R9 and R10 are -F, or R9 and R10 taken together are (O=), which together with the carbon to which they are attached forms a carbonyl group.